FluoGuide has received green light to proceed to fifth dose level with FG001 in the ongoing clinical phase I/II trial in patients with high grade glioma
Copenhagen, Denmark, 8 April 2021 – FluoGuide A/S (“FluoGuide” or the “Company”) is pleased to announce that the dose escalation committee has approved initiation of the fifth dose level in the ongoing clinical phase I/II trial evaluating safety and efficacy of FG001 in patients with high grade glioma undergoing neurosurgery.The results from the patients in the fourth dose level show that FG001 was well tolerated, and the light intensity continues to increase with higher dose levels. Light was detected in all patients. The data from this dose level differed from previous dose levels as